Profusa, Inc.

PFSA Nasdaq CIK: 0001859807

Company Information

Industry Surgical & Medical Instruments & Apparatus
SIC Code 3841
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 207 WEST 25TH ST, 9TH FLOOR, NEW YORK, NY, 10001
Mailing Address 207 WEST 25TH ST, 9TH FLOOR, NEW YORK, NY, 10001
Phone 212-494-9022
Fiscal Year End 1231
EIN 863437271

Financial Overview

FY2024

$10.88M
Total Assets
$16K
Cash & Equivalents
$0.12
EPS

Recent SEC Filings

Form Type Date Filed Document
S-1 IPO registration statement February 13, 2026 View on SEC
8-K Current report of material events February 13, 2026 View on SEC
S-1/A IPO registration amendment February 13, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 9, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
S-1 IPO registration statement February 4, 2026 View on SEC
4 Insider stock transaction report February 2, 2026 View on SEC
4 Insider stock transaction report February 2, 2026 View on SEC
8-K Current report of material events February 2, 2026 View on SEC
4 Insider stock transaction report January 30, 2026 View on SEC

Material Events

8-K Strategy Change February 5, 2026
High Impact
  • Profusa is executing a 1-for-75 reverse stock split to increase its per-share trading price.
  • The primary goal is to regain compliance with Nasdaq's minimum bid price requirement ($1.00) and avoid delisting.
View Analysis
8-K Financial Distress February 2, 2026
High Impact
  • FDA-approved 'Lumos Health Monitor' biosensor for continuous body chemistry tracking.
  • Shareholders approved a reverse stock split to prevent delisting and attract institutional investors.
View Analysis

Related Companies

Companies in the same industry (SIC: 3841)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.